Advanced Medical Isotope Corp. considers pursuing regulatory down-classification for its brachytherapy cancer product.
Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.
Radiosurgery systems maker Accuray lands summary judgment in trade secrets lawsuit filed by former supplier Rotary Systems.
California medtech maker Accuray (NSDQ:ARAY) tallied a win in a trade secrets lawsuit filed by a former supplier, announcing that a Minnesota court awarded summary judgment against Rotary Systems.
Radiosurgery systems maker Varian affirms its 2014 outlook with 5% year-over-year growth in Q1, even as per-share earnings fall short of expectations.
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) started its fiscal year with moderate growth and a reaffirmed outlook on 2014, but per-share earnings fall short of analysts' projections.
Accuray slashes Q2 losses and ups its earnings expectations for the year, prompting a 13% boost from Wall Street.
California radiation oncology systems maker Accuray (NSDQ:ARAY) scored major Wall Street points with its 2nd quarter financial report, with shares soaring on news of lowered losses and increased guidance for the year.
P-Cure signed a development deal with Philips Healthcare to advance its proton therapy using Philips imaging technology.
Philips (NYSE:PHG) aligned itself with Israel-based medical device company P-Cure, in order to advance the smaller firm's proton therapy technology.
Medtech maker ViewRay plans to expand worldwide commercial efforts with $30 million raised from new and existing investors.
Ohio-based ViewRay Inc. is looked to widen its global commercial reach with new funds raised from both new and existing investors.
ViewRay touted $30 million in new funding that the privately held company plans to use to market its ViewRay MRI-guided radiation therapy system around the world.
California's Varian Medical Systems authorizes a share buyback program of up to $6 million in common stock.
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) announced today the authorization of a $6 million common stock buyback program, authorized by its board of directors.